Manufacturing And Supply Chain: Making Space Between A Rock And A Hard Place

By Ben Comer, Chief Editor, Life Science Leader

With the enthusiasm surrounding innovative product types and therapeutic approaches — and the corresponding rush to bring these new products to market — company leaders should double down on internal manufacturing and CDMO oversight to prevent unanticipated delays. Supply chain shortages are likely to continue next year, but biopharma leaders suggest that collaboration with government regulators can help grease the skids; in other scenarios, some of which are described below, operations executives have been able to turn other company’s shortages into their own opportunities.